Income Statement
WEREWOLF THERAPEUTICS, INC.
HOWL
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - |
|
Operating Expenses
|
60.68 | 75.48 | 60.45 | 72.46 | 50.09 |
|
Research & Development
|
44.83 | 56.43 | 41.78 | 53.76 | 35.27 |
|
Selling, General & Administrative
|
15.85 | 19.05 | 18.67 | 18.70 | 14.82 |
|
Other Operating Expenses
|
- | - | - | - | - |
|
Operating Income
|
-60.68 | -75.48 | -60.45 | -72.46 | -50.09 |
|
Non-Operating Income
|
-0.15 | 3.08 | 3.14 | 2.25 | 0.10 |
|
Interest Income
|
3.11 | 6.67 | 7.42 | - | - |
|
Interest Expense
|
5.27 | 3.31 | 3.14 | - | - |
|
Other Non-Op Income / Expense
|
2.02 | 1.62 | -1.14 | - | - |
|
Income Before Tax
|
- | - | - | - | - |
|
Income Tax Expense
|
- | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - |
|
Net Income
|
-60.82 | -70.52 | -37.37 | -53.81 | -49.98 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY |
|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - |
|
EBITDA
|
-60.68 | -75.48 | -60.45 | -72.46 | -50.09 |
|
Earnings Per Share (Basic)
|
-1.32 | -1.63 | -1.05 | -1.86 | -10.94 |
|
Diluted EPS
|
-1.33 | -1.63 | -1.05 | -1.86 | -10.94 |
|
Weighted Average Shares
|
46.02 | 43.33 | 35.65 | 28.86 | 18.46 |
|
Diluted Weighted Avg Shares
|
46.81 | 43.86 | 35.65 | 28.86 | 18.46 |
|
Comprehensive Income
|
- | - | - | - | - |